GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Spexis AG (XSWX:SPEX) » Definitions » Return-on-Tangible-Equity

Spexis AG (XSWX:SPEX) Return-on-Tangible-Equity : 0.00% (As of Jun. 2023)


View and export this data going back to 2018. Start your Free Trial

What is Spexis AG Return-on-Tangible-Equity?

Return-on-Tangible-Equity is calculated as Net Income divided by its average total shareholder tangible equity. Total shareholder tangible equity equals to Total Stockholders Equity minus Intangible Assets. Spexis AG's annualized net income for the quarter that ended in Jun. 2023 was CHF-7.82 Mil. Spexis AG's average shareholder tangible equity for the quarter that ended in Jun. 2023 was CHF-6.25 Mil. Therefore, Spexis AG's annualized Return-on-Tangible-Equity for the quarter that ended in Jun. 2023 was N/A%.

The historical rank and industry rank for Spexis AG's Return-on-Tangible-Equity or its related term are showing as below:

During the past 10 years, Spexis AG's highest Return-on-Tangible-Equity was 26.52%. The lowest was -614.36%. And the median was -77.00%.

XSWX:SPEX's Return-on-Tangible-Equity is not ranked *
in the Biotechnology industry.
Industry Median: -46.86
* Ranked among companies with meaningful Return-on-Tangible-Equity only.

Spexis AG Return-on-Tangible-Equity Historical Data

The historical data trend for Spexis AG's Return-on-Tangible-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Spexis AG Return-on-Tangible-Equity Chart

Spexis AG Annual Data
Trend Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
Return-on-Tangible-Equity
Get a 7-Day Free Trial Premium Member Only Premium Member Only -81.04 -76.54 -8.90 - -

Spexis AG Semi-Annual Data
Dec13 Dec14 Dec15 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23
Return-on-Tangible-Equity Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Spexis AG's Return-on-Tangible-Equity

For the Biotechnology subindustry, Spexis AG's Return-on-Tangible-Equity, along with its competitors' market caps and Return-on-Tangible-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Spexis AG's Return-on-Tangible-Equity Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Spexis AG's Return-on-Tangible-Equity distribution charts can be found below:

* The bar in red indicates where Spexis AG's Return-on-Tangible-Equity falls into.



Spexis AG Return-on-Tangible-Equity Calculation

Spexis AG's annualized Return-on-Tangible-Equity for the fiscal year that ended in Dec. 2022 is calculated as

Return-on-Tangible-Equity=Net Income/( (Total Tangible Equity+Total Tangible Equity)/ count )
(A: Dec. 2022 )  (A: Dec. 2021 )(A: Dec. 2022 )
=Net Income/( (Total Stockholders Equity - Intangible Assets+Total Stockholders Equity - Intangible Assets )/ count )
(A: Dec. 2022 )  (A: Dec. 2021 )(A: Dec. 2022 )
=-18.553/( (1.542+-5.298 )/ 2 )
=-18.553/-1.878
=N/A %

Spexis AG's annualized Return-on-Tangible-Equity for the quarter that ended in Jun. 2023 is calculated as

Return-on-Tangible-Equity=Net Income/( (Total Tangible Equity+Total Tangible Equity)/ count )
(Q: Jun. 2023 )  (Q: Dec. 2022 )(Q: Jun. 2023 )
=Net Income/( (Total Stockholders Equity - Intangible Assets+Total Stockholders Equity - Intangible Assets)/ count )
(Q: Jun. 2023 )  (Q: Dec. 2022 )(Q: Jun. 2023 )
=-7.818/( (-5.298+-7.195)/ 2 )
=-7.818/-6.2465
=N/A %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Return-on-Tangible-Equity, the net income of the last fiscal year and the average total shareholder tangible equity over the fiscal year are used. In calculating the quarterly data, the net income data used here is two times the semi-annual (Jun. 2023) net income data. Return-on-Tangible-Equity is displayed in the 10-year financial page.


Spexis AG  (XSWX:SPEX) Return-on-Tangible-Equity Explanation

Return-on-Tangible-Equity measures the rate of return on the ownership interest (shareholder's tangible equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' tangible equity (shareholders equity minus intangibles). Return-on-Tangible-Equity shows how well a company uses investment funds to generate earnings growth. Return-on-Tangible-Equitys between 15% and 20% are considered desirable.


Be Aware

Net Income is used.

Because a company can increase its Return-on-Tangible-Equity by having more financial leverage, it is important to watch the leverage ratio when investing in high Return-on-Tangible-Equity companies. Like Return-on-Tangible-Asset, Return-on-Tangible-Equity is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.

Asset light businesses require very few assets to generate very high earnings. Their Return-on-Tangible-Equitys can be extremely high.


Spexis AG Return-on-Tangible-Equity Related Terms

Thank you for viewing the detailed overview of Spexis AG's Return-on-Tangible-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.


Spexis AG (XSWX:SPEX) Business Description

Industry
Traded in Other Exchanges
Address
Hegenheimermattweg 125, Allschwil, CHE, CH-4123
Spexis AG is a clinical-stage biopharmaceutical company. The company is engaged in the discovery and development of antibiotics and other specialty pharma products for severe or life-threatening diseases. The company's lead product, murepavadin, is in Phase III development against Pseudomonas aeruginosa - recognized as a critical priority 1 pathogen by World Health Organization. It has one operating segment focusing on the research and development and prospective commercialization of respiratory therapeutics addressing high unmet medical needs.

Spexis AG (XSWX:SPEX) Headlines

No Headlines